Duncan F Rogers

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. pmc Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells
    Jeanclare Seagrave
    Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108, USA
    Respir Res 13:98. 2012
  2. ncbi request reprint Mucoactive agents for airway mucus hypersecretory diseases
    Duncan F Rogers
    Airway Disease, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, United Kingdom
    Respir Care 52:1176-93; discussion 1193-7. 2007
  3. ncbi request reprint Physiology of airway mucus secretion and pathophysiology of hypersecretion
    Duncan F Rogers
    Airway Disease, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London, United Kingdom, SW3 6LY
    Respir Care 52:1134-46; discussion 1146-9. 2007
  4. ncbi request reprint The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, Dovehouse St, London SW3 6LY, UK
    COPD 2:341-53. 2005
  5. ncbi request reprint Treatment of airway mucus hypersecretion
    Duncan F Rogers
    Section of Airway Disease, National Heart and Lung Institute, Imperial College London, UK
    Ann Med 38:116-25. 2006
  6. ncbi request reprint Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Pulm Pharmacol Ther 18:1-8. 2005
  7. ncbi request reprint Airway mucus hypersecretion in asthma: an undervalued pathology?
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Curr Opin Pharmacol 4:241-50. 2004
  8. ncbi request reprint Pulmonary mucus: Pediatric perspective
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Pediatr Pulmonol 36:178-88. 2003
  9. ncbi request reprint Airway hypersecretion in allergic rhinitis and asthma: new pharmacotherapy
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK
    Curr Allergy Asthma Rep 3:238-48. 2003
  10. doi request reprint New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways
    HonYee Lai
    Airway Disease, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    J Aerosol Med Pulm Drug Deliv 23:219-31. 2010

Collaborators

  • Peter J Barnes
  • L E Donnelly
  • D J Thornton
  • Sarah V Culpitt
  • Jeanclare Seagrave
  • HonYee Lai
  • Hon Yee Lai
  • Karine Rousseau
  • Catherine R Gwilt
  • Sumalatha Grandhi
  • Carmen De Matos
  • Julia A Nightingale
  • Helmut H Albrecht
  • David B Hill
  • Gail Solomon
  • Peter Clegg
  • Brian Fitzpatrick
  • David Knight
  • Lindsay Johnson
  • Marj Howard
  • Emily J Adams
  • Sara Kirkham
  • Pallav Shah
  • Richard E K Russell
  • Richard E Russell

Detail Information

Publications23

  1. pmc Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells
    Jeanclare Seagrave
    Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108, USA
    Respir Res 13:98. 2012
    ..We examined the effects of guaifenesin (GGE), N-acetylcysteine (NAC) and ambroxol (Amb) on differentiated human airway epithelial cells stimulated with IL-13 to produce additional MUC5AC...
  2. ncbi request reprint Mucoactive agents for airway mucus hypersecretory diseases
    Duncan F Rogers
    Airway Disease, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, United Kingdom
    Respir Care 52:1176-93; discussion 1193-7. 2007
    ..It is noteworthy that, of the more complex molecules in development, it is simple inhaled hypertonic saline that is currently receiving the greatest attention as a mucus therapy, primarily in CF...
  3. ncbi request reprint Physiology of airway mucus secretion and pathophysiology of hypersecretion
    Duncan F Rogers
    Airway Disease, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London, United Kingdom, SW3 6LY
    Respir Care 52:1134-46; discussion 1146-9. 2007
    ....
  4. ncbi request reprint The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, Dovehouse St, London SW3 6LY, UK
    COPD 2:341-53. 2005
    ....
  5. ncbi request reprint Treatment of airway mucus hypersecretion
    Duncan F Rogers
    Section of Airway Disease, National Heart and Lung Institute, Imperial College London, UK
    Ann Med 38:116-25. 2006
    ..More information is required on these differences to identify specific therapeutic targets which, in turn, should lead to rational design of anti-hypersecretory drugs for treatment of airway mucus hypersecretion in asthma and COPD...
  6. ncbi request reprint Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Pulm Pharmacol Ther 18:1-8. 2005
    ..Finally, a number of novel targets for the treatment of airway mucociliary dysfunction have been identified, and targeting agents are currently in development...
  7. ncbi request reprint Airway mucus hypersecretion in asthma: an undervalued pathology?
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Curr Opin Pharmacol 4:241-50. 2004
    ..There is currently huge research interest in identifying targets involved in inducing mucus abnormalities, which should lead to the rational design of anti-hypersecretory drugs for treatment of airway mucus hypersecretion in asthma...
  8. ncbi request reprint Pulmonary mucus: Pediatric perspective
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Pediatr Pulmonol 36:178-88. 2003
    ..A significant challenge to the therapeutic progression of these new compounds is effective delivery to the airways in children, with the research effort into development of new compounds matched by advances in inhaler design...
  9. ncbi request reprint Airway hypersecretion in allergic rhinitis and asthma: new pharmacotherapy
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK
    Curr Allergy Asthma Rep 3:238-48. 2003
    ..Data from clinical trials with blockers of these targets are awaited with great interest, not only for disease management but also to determine the clinical benefit of selective inhibition of airway hypersecretion...
  10. doi request reprint New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways
    HonYee Lai
    Airway Disease, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    J Aerosol Med Pulm Drug Deliv 23:219-31. 2010
    ..This may be accomplished by maximizing airway selectivity, which may be facilitated by appropriate delivery device design...
  11. doi request reprint Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy
    Hon Yee Lai
    National Heart and Lung Institute, Imperial College London, UK
    Curr Opin Allergy Clin Immunol 10:67-76. 2010
    ..This review identifies intracellular signalling pathways as rational targets for treatment of excessive airway mucus production...
  12. ncbi request reprint Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease
    Sarah V Culpitt
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom
    Am J Respir Crit Care Med 165:1371-6. 2002
    ..These results suggest that theophylline has antiinflammatory properties that may be useful in the long-term treatment of COPD...
  13. ncbi request reprint The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation?
    Catherine R Gwilt
    Airway Disease, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, United Kingdom
    Pharmacol Ther 115:208-22. 2007
    ..The non-neuronal cholinergic system of airway inflammatory cells represents a previously unappreciated regulatory pathway, with immunomodulatory effects that potentially influence the inflammation of asthma and COPD...
  14. ncbi request reprint Mucoactive drugs for asthma and COPD: any place in therapy?
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute Imperial College, Dovehouse Street, London SW3 6LY, UK
    Expert Opin Investig Drugs 11:15-35. 2002
    ..Cost-effective treatment would be in patients with poor lung function who have frequent or prolonged exacerbations or are repeatedly admitted to hospital...
  15. ncbi request reprint Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease
    Sarah V Culpitt
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom
    Am J Respir Crit Care Med 167:24-31. 2003
    ..We conclude that the lack of efficacy of corticosteroids in COPD might be due to the relative steroid insensitivity of macrophages in the respiratory tract...
  16. ncbi request reprint Therapy for chronic obstructive pulmonary disease in the 21st century
    Louise E Donnelly
    Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, UK
    Drugs 63:1973-98. 2003
    ..The current scarcity of well characterised surrogate markers predicts that long-term studies in large numbers of patients will be needed to monitor changes in disease progression...
  17. ncbi request reprint The airway goblet cell
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute Imperial College, Dovehouse Street, London, SW3 6LY, UK
    Int J Biochem Cell Biol 35:1-6. 2003
    ....
  18. ncbi request reprint Pharmacological regulation of the neuronal control of airway mucus secretion
    Duncan F Rogers
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, SW3 6LY, UK
    Curr Opin Pharmacol 2:249-55. 2002
    ..None of these inhibitory options are currently being targeted specifically for therapy of airway hypersecretion...
  19. ncbi request reprint Comparison of the effects of salmeterol and formoterol in patients with severe asthma
    Julia A Nightingale
    Department of Thoracic Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, London, UK
    Chest 121:1401-6. 2002
    ..However, to date there have been no trials comparing the efficacy of salmeterol and formoterol in patients with severe asthma...
  20. ncbi request reprint Phytoceuticals: the new 'physic garden' for asthma and chronic obstructive pulmonary disease
    Sumalatha Grandhi
    Airway Disease, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Expert Rev Respir Med 1:227-46. 2007
    ..Well-designed clinical trials are required to determine whether these beneficial activities are reproduced in patients, with the prospect that phytoceuticals are the new physic garden for asthma and COPD...
  21. ncbi request reprint Airway goblet cell hyperplasia in asthma: hypersecretory and anti-inflammatory?
    Duncan F Rogers
    Clin Exp Allergy 32:1124-7. 2002
  22. doi request reprint Novel targets and drugs in inflammatory lung disease
    Louise E Donnelly
    Curr Opin Pharmacol 8:219-21. 2008
  23. doi request reprint Proteomic analysis of polymeric salivary mucins: no evidence for MUC19 in human saliva
    Karine Rousseau
    Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, The Michael Smith Building, University of Manchester, Manchester M13 9PT, UK
    Biochem J 413:545-52. 2008
    ..Our results suggest that unlike human saliva, which contains MUC5B, cow, horse and rat saliva are a heterogeneous mixture of Muc5b and Muc19. The functional consequence of these species differences remains to be elucidated...